What to Expect from Amarin’s Expenses in 2018

Currently, Amarin (AMRN) is focused on creating awareness for Vascepa across new territories. According to Amarin’s third-quarter earnings conference call, the company is initially targeting territories that have the potential to become profitable in a short timeframe. Amarin has been targeting ~20,000 general practitioners to increase Vascepa’s adoption. General practitioners are the first physicians that patients visit when they’re suffering from high cardiovascular risk. General practitioners account for almost 85% of the total physicians that Amarin is targeting. Among the remaining physicians, ~7% are cardiologists and 5% are endocrinologists.